3 Reasons Exelixis, Inc. Could Excel in 2014

Exelixis has rallied strongly over the past 12 months, despite only having a single approved drug, which is only expected to generate $50 million in peak revenues. Can the stock continue soaring thanks to these 3 catalysts, and how does its future involve AstraZeneca, Johnson & Johnson, Medivation, and Roche?

Jan 16, 2014 at 6:30PM

Shares of Exelixis (NASDAQ:EXEL), a biotech company focused on small molecule treatments for cancer, have performed exceptionally well over the past 12 months, rallying more than 70% even though its one approved drug, Cometriq, is hardly expected to be a blockbuster.

Why has Exelixis, which once traded in the mid-$40s prior to the dot-com crash of 2000, suddenly generated so much bullish interest?

EXEL Chart

Source: YCharts.

Let's take a closer look at the company, how companies like AstraZeneca (NYSE:AZN), Johnson & Johnson (NYSE:JNJ), Medivation (NASDAQ:MDVN), and Roche (NASDAQOTH:RHHBY) could affect its future and three potential catalysts that could propel the stock to higher levels in 2014.

Exelixis in a nutshell
Exelixis' only marketed drug, Cometriq, was approved by the FDA in November 2012. The drug is approved to treat metastatic medullary thyroid cancer (MTC).

This was a major development because there are very few approved treatments that specifically that target that rare type of thyroid cancer -- traditional treatments consist of surgery followed by hormone therapy, radiation therapy, and chemotherapy.

Cometriq's only true competitor on the market is AstraZeneca's Caprelsa, a drug that was approved in the U.S. in 2011 and in Europe in 2012 for the same indication. Off-label competitors for metastatic MTC include Bayer and Amgen's Nexavar and Pfizer's Sutent.

Due to the rarity of MTC, which only accounts for 3% to 4% of all thyroid cancer cases in the United States, peak sales estimates of Cometriq are low at around $50 million. Between the commercial launch of Cometriq in January 2013 and the end of the third quarter on Sept. 30, 2013, Exelixis only reported $10.7 in revenues from the drug.

As expected, the company's financial condition is a bit precarious, with $279 million in cash being weighed down by $342 million in debt and a negative operating cash flow of $190 million.

Yet the stock has soared, giving it a lofty price-to-sales ratio of 41 and price-to-book ratio of 11. Why are investors willing to give Exelixis the benefit of the doubt and look past its lackluster sales growth and feverish fundamentals?

1. Additional approvals could unlock Cometriq's true value
The main thing to remember about Exelixis is that MTC was only expected to be the first of several approved indications. Here are the other main indications that the company is pursuing for the drug:




Prostate cancer

Previously treated, castration-resistant, metastatic or symptomatic

Phase 3, recruiting

Hepatocellular carcinoma

Previously treated

Phase 3, recruiting

Renal cell carcinoma

Previously treated

Phase 3, recruiting

Non-small cell lung cancer (NSCLC)

Advanced (stage IV)

Phase 2, active

Source: Company website.

With three major indications, especially prostate cancer, entering late-stage trials, Cometriq's growth potential cannot be ignored. If approved for the prostate cancer indication, analysts forecast that it could be an instant blockbuster, hitting peak sales of $1.6 billion.

The most compelling reason to believe that Cometriq can be approved is the fact that phase 2 data showed a median overall survival rate of 10.8 months in a population where 73% of the patients had two or more prior therapies.

While this can't match the 18.4 months that Medivation/Astellas' Xtandi has accomplished or the 15.8 months claimed by Johnson & Johnson's Zytiga, it's still enough to warrant a possible FDA approval.

There are two main reasons that it could be approved:

  • There aren't that many late-stage prostate cancer treatments on the market -- the majority of the market has been split between three major drugs -- Xtandi, Zytiga, and Dendreon's Provenge.

  • According to its COMET-1 and COMET-2 phase 3 trials, Exelixis is testing the treatment only on patients who have failed a treatment with Zytiga, Xtandi, or Sanofi's chemotherapy drug Taxotere -- which means it might not have to compete at all against the dominant treatments.

Top-line data from both COMET trials are expected later this year -- which would be a major near-term catalyst for the stock.

Meanwhile, additional approvals of hepatocellular carcinoma and renal cell carcinoma could further solidify Cometriq's blockbuster status.

2. A possible European approval in 2014
Although Exelixis' current market of metastatic MTC in the U.S. is small, a possible approval in Europe could easily double Cometriq sales.

So far, things look good -- last month, Exelixis announced that the European Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion regarding its marketing authorization application (MAA) for Cometriq for the same metastatic MTC indication.

If approved by the European Commission, Cometriq should be commercialized quickly, thanks to a previously signed commercialization agreement with Swedish Orphan Biovitrum (Sobi) in 2013.

Most importantly, an approval in Europe would help Cometriq gain ground against Caprelsa, which only generated $27 million in sales in fiscal 2012.

3. Major pharmaceutical collaborators
The last major catalyst for Exelixis is its strength in major pharmaceutical collaborations.

Its first main drug beyond Cometriq is GDC-0973 (XL518), a drug which is being developed by Roche's Genentech unit under a collaboration agreement with Exelixis. Exelixis handled the drug through the end of phase 1 trials, after which it was transferred over to Genentech.

XL518 is a signalling pathway inhibitor which could have multiple applications in a variety of cancers. The drug is being tested first in a phase 3 trial as a late-stage skin cancer treatment in combination with Roche's Zelboraf.

If approved, Exelixis is entitled to 50% of the profits from the first $200 million in U.S. sales and 30% of the profits from U.S. sales up to $400 million. Exelixis is also entitled to low double-digit royalties on overseas sales.

In addition to Roche, Exelixis holds partnerships in compounds manufacturing with GlaxoSmithKline, Sanofi, Daiichi-Sankyo, Bristol-Myers Squibb, and Merck.


Source: Company website.

Together, these collaborations have the potential to yield milestone payments of up to $2.4 billion.

Exelixis anticipates 10%, 41%, and 49% of those payments to respectively come from clinical development, regulatory, and commercial milestones. Those payments could support the top line for Exelixis, which has only generated $27 million in revenue in the first three quarters of 2013.

More importantly, the backing of all these major companies bodes well for a smaller biotech company like Exelixis.

The Foolish takeaway
In closing, Exelixis is a risky stock with lots of upside potential if Cometriq is approved for additional indications beyond metastatic MTC. However, the company's financial position is a bit shaky, and could lead to additional share-diluting stock offerings.

For now, good news about its prostate cancer progress and an approval in Europe could cause the stock to rally in the near term. Meanwhile, Exelixis' collaborations with major pharmaceutical companies should provide it with a small cash cushion if times get tough.


Want to learn more about the health-care industry and Obamacare?
Obamacare seems complex, but it doesn't have to be. In only minutes, you can learn the critical facts you need to know in a special free report called "Everything You Need to Know About Obamacare." This FREE guide contains the key information and money-making advice that every American must know. Please click here to access your free copy.


Fool contributor Leo Sun has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Exelixis and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information